Inhibrx

INBX53

$15.45arrow_drop_down6.57%-$1.08

INBX53

$15.45

arrow_drop_down6.57%-$1.08

Performance History

Key Stats
Open	$16.32
Prev. Close	$16.21
EPS	118.84
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$236.24M

	LOW	HIGH
Day Range	15.88	16.59
52 Week Range	10.80	39.79

Ratios







EPS	118.84

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Inhibrx (INBX)

Inhibrx, Inc. (INBX) is a biotechnology company that focuses on the discovery and development of innovative therapeutics for the treatment of cancer and other diseases. The company's mission is to improve the lives of patients by delivering novel, targeted therapies that address significant unmet medical needs. Inhibrx employs a multi-modal approach to drug development, leveraging its proprietary technologies and expertise in protein engineering, immunology, and oncology.

One of Inhibrx's key therapeutic candidates is INBX-001, a first-in-class antibody-drug conjugate (ADC) targeting CD47, a protein overexpressed in many types of cancer. CD47 acts as a "don't eat me" signal to the immune system, allowing cancer cells to evade immune detection and destruction. INBX-001 consists of an anti-CD47 antibody linked to a potent cytotoxic payload, which selectively kills CD47-positive cancer cells while sparing healthy cells. Preclinical studies have demonstrated promising anti-tumor activity and a favorable safety profile for INBX-001.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Mark Paul Lappe
Headquarters: La Jolla
Employees: 132
Exchange: NASDAQ

Keep an eye on Inhibrx

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Inhibrx's (INBX) price per share?

The current price per share for Inhibrx (INBX) is $15.45. The stock has seen a price change of -$1.09 recently, indicating a -6.57% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Inhibrx (INBX)?

For Inhibrx (INBX), the 52-week high is $39.79, which is 157.54% from the current price. The 52-week low is $10.8, the current price is 43.06% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Inhibrx (INBX) a growth stock?

Inhibrx (INBX) has shown an average price growth of -3.13% over the past three years. It has received a score of 16 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Inhibrx as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Inhibrx (INBX) stock price performance year to date (YTD)?

As of the latest data, Inhibrx (INBX) has a year-to-date price change of -59.38%. Over the past month, the stock has experienced a price change of -0.32%. Over the last three months, the change has been 36.73%. Over the past six months, the figure is -54.63%.

help

Is Inhibrx (INBX) a profitable company?

Inhibrx (INBX) has a net income of -$241.36M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 33.83% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -160.9K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $1.8M, although specific revenue growth data is currently not available. The gross profit is $609K. Operating income is noted at -$219.22M. Furthermore, the EBITDA is -$300.93M.

help

What is the market capitalization of Inhibrx (INBX)?

Inhibrx (INBX) has a market capitalization of $237.19M. The average daily trading volume is 16.1, indicating the stock's liquidity and investor engagement.